Clinical medicine profile
Ambroxal+Guaphensin+Salbutamol
Beta-2 adrenergic agonist (bronchodilator)
- Route
- INHALATION / ORAL / NEB / IV (rare)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
A traceable source link is not attached to this profile. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Ambroxal] Hypersensitivity.
- LABA monotherapy in asthma is contraindicated — always with ICS. [Salbutamol] Hypersensitivity.
- LABA monotherapy in asthma is contraindicated — always with ICS.
Precautions
- Paradoxical bronchospasm.
- Hypokalaemia with high dose/nebs especially with steroids/diuretics/xanthines.
- CV disease: tachycardia/arrhythmia risk.
- Thyrotoxicosis caution.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Adults and Adolescents over 12 years of age: 5 mL to 10 mL BD to TID. Children 6 to 12 years of age: 2.5 mL to 5 mL BD to TID.
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Low for inhaled; monitor electrolytes if continuous nebs.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Low clinical concern for inhaled therapy.
Use, effects & interactions
Indications
- Therapeutic use is agent- and indication-specific within the class (Beta-2 adrenergic agonist (bronchodilator)).
- Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC.
- A cough that requires expectoration
Adverse effects
- [Ambroxal] Tremor, tachycardia, headache, palpitations, hypokalaemia, hyperglycaemia.
- Serious: arrhythmias, paradoxical bronchospasm. [Salbutamol] Tachycardia, skeletal muscle cramp, palpitation, headaches, severe emotional disturbances, resistance after prolonged use, acidosis, GI disturbances, hypokaleamia, sweat
Drug interactions
Open multi-drug checker ↗- [Ambroxal] Assess inhaler technique every visit.
- Increasing SABA use = uncontrolled disease — step up controller therapy.
- Never prescribe LABA alone for asthma. [Salbutamol] Assess inhaler technique every visit.
- Increasing SABA use = uncontrolled disease — step up controller therapy.
- Never prescribe LABA alone for asthma.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Salbutamol): Stimulates airway beta-2 receptors → smooth muscle relaxation and bronchodilation. Stimulate airway smooth muscle beta-2 receptors, increasing cAMP and causing bronchodilation. Also improve mucociliary clearance and may stabilise mast cells. SABA for rescue; LABA for maintenance with ICS.
Minutes (SABA)
3–6 h SABA; 12 h LABA
INHALATION / ORAL / NEB / IV (rare)
causes tremor/tachycardia. Hepatic
of many agents. [Salbutamol] Inhaled route maximises lung delivery and reduces systemic effects. Systemic
Pregnancy, lactation & diet
[Ambroxal] Inhaled salbutamol widely used; uncontrolled asthma risk > drug risk. [Salbutamol] Inhaled salbutamol widely used; uncontrolled asthma risk > drug risk.
Inhaled therapy generally compatible.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.